Prescribing Information for Gardasi|®9 (Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)): United Kingdom

By clicking the link above, you will leave this page and be taken to the EMC PI portal website.

HPV AND HPV VACCINATION FOR ADULTS

GARDASIL®9 THERAPEUTIC INDICATION¹

GARDASIL®9 is indicated for active immunisation of individuals from the age of 9 years against the following HPV diseases:

• Premalignant lesions and cancers affecting the cervix, vulva, vagina and anus caused by vaccine HPV types

• Genital warts (Condyloma acuminata) caused by specific HPV types¹

Please consult the Summary of Product Characteristics (SmPC) before prescribing or delivering the product. The use of GARDASIL®9 should be in accordance with official recommendations.¹

Adverse events should be reported.

Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to MSD (Tel: 020 8154 8000).

Merck Sharp & Dohme (UK) Limited Registered Office: 120 Moorgate, London, EC2M 6UR, United Kingdom. Registered in England No. 233687 Copyright © 2024 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.​

GB-GSL-00823 | Date of preparation: October 2025